Alnylam Pharmaceuticals, Inc.
ALNY· Nasdaq
ALNYAlnylam Pharmaceuticals, Inc.
Source filing unavailable
| Metric | Q2 2011 | Q2 2010 | Q2 2009 |
|---|---|---|---|
| Revenue | — | $26.62M | $24.60M |
| Net Income | -$13.82M | -$14.63M | -$22.70M |
| EPS Diluted | -$0.33 | -$0.35 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
